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The 2007 American Society of Transplant Surgeons’
(ASTS) State-of-the-Art Winter Symposium entitled,
‘Solving the Organ Shortage Crisis’ explored ways
to increase the supply of donor organs to meet the
challenge of increasing waiting lists and deaths while
awaiting transplantation. While the increasing use of
organs previously considered marginal, such as those
from expanded criteria donors (ECD) or donors after
cardiac death (DCD) has increased the number of trans-
plants from deceased donors, these transplants are
often associated with inferior outcomes and higher
costs. The need remains for innovative ways to in-
crease both deceased and living donor transplants.
In addition to increasing ECD and DCD utilization, in-
creasing use of deceased donors with certain types
of infections such as Hepatitis B and C, and increas-
ing use of living donor liver, lung and intestinal trans-
plants may also augment the organ supply. The extent
by which donors may be offered incentives for dona-
tion, and the practical, ethical and legal implications
of compensating organ donors were also debated. The
expanded use of nonstandard organs raises potential
ethical considerations about appropriate recipient se-
lection, informed consent and concerns that the cur-
rent regulatory environment discourages and penal-
izes these efforts.
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Introduction
Organ transplantation has in some ways become a vic-
tim of its success. Life-saving organ replacement therapy
has been offered to an increasingly complex population of
patients with an increasing success rate. As a result, the
number of transplants performed annually is dwarfed by
the number awaiting transplantation. In addition, the num-
ber of deaths that occur while awaiting transplantation ap-
proaches the number of patients transplanted each year
(1). Currently, there is an ongoing increase in the number of
patients who are awaiting kidney transplantation, while the
number of patients on the liver transplant list has been sta-
ble. Despite this stability, there are ongoing deaths among
patients on the waiting list. The transplantation community
has responded by developing various strategies to expand
the pool of available organs including the utilization of ex-
tended criteria donors (ECD), donation after cardiac death
(DCD) and live donor (LD) transplantation. The 7th Annual
American Society of Transplant Surgeons State-of-the-Art
Winter Symposium explored the implications of expanding
the donor pool in this manner including donor and recipi-
ent risk factors, the concept of ‘net benefit’, outcomes and
ethical considerations associated with implementation of
these strategies.
The scope of organ donation and the complexity of poten-
tial solutions to the shortage of organs for transplantation
preclude comprehensive reporting of all possible solutions
in this report. We have attempted to present a balanced
representation of the information discussed at the sympo-
sium. However, many of the strategies reviewed are pro-
posals or in the very early stages of clinical implementa-
tion. Some of the information represents the opinions of
the individual speakers, and while these opinions are well
informed, we acknowledge that some of the opinions are
likely to be subject to debate.
Defining the problem
Although the number of donors in the United States has in-
creased steadily over the past decade, the age and source
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Figure 1: Age distribution of US donors over time. The change
in age distribution of organ donors that has occurred in the United
States over the past decade is shown. Donors under the age 40
years have remained stable while donors over 40 years have in-
creased significantly.
distribution have undergone significant changes. The ef-
fect of these changes was reviewed by John Roberts (Uni-
versity of California, San Francisco). Currently, more than
60% of donors are 40 years of age or older while the
number of younger donors has remained relatively static
(Figure 1) (1). This finding is similar to that previously ob-
served in Spain when a marked increase in the number
of donors occurred during the 1990s (2). Examination of
the US data also demonstrates that a significant portion
of the increased donation from younger donors is the re-
sult of increased utilization of DCD donors (3). While the
use of DCD and older donors has obviously increased the
number of organs available for transplantation, the prac-
tice presents new challenges to both the recipients of the
expanded criteria organs and their physicians.
Robert Merion of the University of Michigan discussed the
evolution of death on the waiting list. To some extent the
use of marginal organs has been successful in prevent-
ing waitlist deaths, since their number has remained sta-
ble since 2002. While the number of deaths of candidates
awaiting kidney transplant has continued to increase, the
numbers have decreased for heart, lung, and heart-lung
transplant candidates. The number of deaths among candi-
Table 1: Number of candidate deaths on waitlist by organ per year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Organ
Kidney 1949 2184 2528 3320 3125 3375 3729 3853 4038 4156
Liver 1103 1274 1565 2017 2018 2324 2160 2087 2145 2104
Heart 802 838 859 804 686 716 631 586 525 465
Lung 420 437 520 600 518 532 529 489 514 394
Pancreas 7 11 21 14 17 35 30 35 51 55
Kidney/Pancreas 95 124 108 169 198 228 223 208 224 206
Intestine 24 44 48 47 27 44 52 48 56 57
Heart-Lung 52 63 43 55 46 42 42 20 29 27




























Figure 2: Waiting list deaths by organ, 1996–2005. The inci-
dence of death while awaiting transplant for various categories
of candidates is shown. Deaths among kidney candidates have
steadily increased, while a decrease was seen for heart, lung or
heart lung candidates. The death rates while waiting have been
relatively stable for other types of candidates.
dates awaiting liver, pancreas, combined kidney-pancreas
or intestinal transplantation has remained relatively stable
(Figure 2, Table 1). Despite these changes in the number
of waiting list deaths by organ, death rates (i.e. numbers of
deaths per patient-years at risk) for heart, liver and kidney
candidates have remained the same since 2000.
The assessment of waiting list deaths is complicated by
the significant and increasing percentage of inactive wait-
ing list candidates. These candidates, who comprised over
20% of the kidney and liver waiting lists in 2005, have
higher mortality risk than those candidates who are active
(adjusted HR = 2.31 for kidney, 4.87 for liver, SRTR Special
Analysis, 2007). However, because a significant majority
of listed patients are active, deaths among inactive can-
didates contribute less to the overall death rates on the
waiting list than do those of active candidates (Figures 3A
and B). In addition, death rates for inactive liver and kid-
ney candidates are decreasing; this (especially in light of
the increase in the percentage of inactive candidates) may
be a consequence of changes in waiting list status man-
agement rather than improvements in pretransplant care.
These trends suggests that a significant proportion of wait-
list deaths continue to be among those candidates who
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Figure 3: (A) Kidney waiting list
death rates by active inactive and
year, 1996–2005, and (B) Liver
waiting list deaths by active inac-
tive and year, 1996–2006. The effect
of death among inactive candidates
on overall waitlist mortality for kidney
(A) and liver (B) candidates is demon-
strated. Although the death rates
among active candidates are signif-
icantly greater for both groups (p =
<0.05) compared to deaths in the to-
tal or the active cohorts, the num-
ber of inactive candidates is small
and removal does not result in signif-
icant differences in the death rates
between the total and active candi-
dates.
were intended to, and were in fact eligible to, receive a
transplant.
One challenge is that transplantation with ECD or DCD
organs results in significant cost increases compared to
transplantation with standard criteria donors. Data pre-
sented by Schnitzler (St. Louis University) demonstrated
that kidney transplantation results in a cost saving when
compared to dialysis, and that live donor kidney transplan-
tation with its shorter waiting times, less dialysis time
and improved organ quality enhances the cost savings
(Figure 4) (4). However, when cost savings is examined
in terms of donor organ source, differences are apparent
(Figure 5). While transplantation is less costly than dialysis
in all instances, transplantation with standard criteria kid-
neys results in significantly greater savings as measured
by dollars per quality-adjusted life-year than transplantation
with either DCD or ECD kidneys (Figure 3). A similar effect
is seen in liver transplantation; patients transplanted with
DCD livers had significantly increased length of stay and
therefore costs when compared to those receiving stan-
dard criteria livers (Table 2).
A second challenge that arises with the utilization of non-
standard donor organs is: ‘Which patients should be of-
fered these organs?’ There is agreement that patients who
would benefit from transplantation can be accurately iden-
tified. There is, however, no consensus regarding the type
and quality of organs that should be offered to various
recipients. Several of the participants reviewed exist-
ing practices and strategies designed to answer these
questions.
John Magee (University of Michigan) outlined the eth-
ical considerations involved in various organ allocation
schemes and reviewed the existing data. He pointed out
that any allocation scheme would be complicated by the
fact that the transplant community’s perception of bene-
fit and a transplant patient’s perception of benefit is likely
to differ in many instances. As an example he offered the
case of a patient given a 5% chance of survival without
transplantation and a 20% chance of survival with trans-
plantation. The patient will see transplantation, as being
in his best interest while the transplant provider will likely
have greater doubts. Some allocation proposals focus on
the benefit potential of a donor organ as a significant fac-
tor in recipient selection. These proposals would allocate
an organ with a potential survival of 30 years to recipi-
ents with similar expected longevity. The ideal allocation
scheme would balance individual justice, instances of ur-
gency, and utility—doing the most good for most of the
people. While the ideal was agreed upon, the mechan-
ics of achieving it remained elusive despite considerable
discussion.
Outcomes in recipients of nonstandard donors
For adult liver transplantation, Feng et al. (5) have de-
veloped the ‘donor risk index’ (DRI)—a semi-quantitative
estimate of the likelihood of liver failure following
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Figure 4: Cost savings of various types of kidney transplant
compared to maintenance dialysis. Cost savings achieved by
transplantation with either a deceased or living donor kidney com-
pared to maintenance dialysis.
transplantation. They showed that factors such as donor
age, DCD status and use of partial liver grafts are associ-
ated with a greater risk of graft loss than transplantation
with a standard criteria donor (SCD) liver. Risks are cate-
gorized as high, medium or low. Two distinct schools of
thought have emerged regarding the use of higher risk or-
gans. The first is to transplant these livers into patients with
low MELD scores in the hope that their relative good health
will allow them to withstand poor allograft function and still
survive. The alternative approach is to use these organs in
sicker patients with higher MELD scores because they are
more likely to die without a liver transplant.
The concern voiced about using the higher risk livers in
sicker patients is that they would do less well with these
grafts because they would lack the physiologic reserves
to withstand poor function. Data from Schaubel et al. (6)
examined the effect of DRI scores on survival across all
MELD ranges. Figure 4 compares the effect of remaining
on the waitlist to transplantation with a low, medium or
high DRI liver at various MELD scores. He showed that
at any given MELD score, use of a high DRI liver pro-
Table 2: Impact of DCD donor on liver transplantation costs
Length of stay (Days)
MELD Estimated
category DCD DBD cost increase
0–10 18.1 17.6 $2264
11–20 19.0 16.2 $12 681
21–30 20.8 18.8 $9058
31–35 34.7 28.9 $26 268

















Figure 5: Costs associated with transplantation of standard
criteria versus ECD or DCD kidneys. Comparison of costs as-
sociated with transplantation with standard, ECD or DCD kidneys
compared to ongoing dialysis. All types of transplantation result in
cost savings compared to dialysis (p < 0.05), but transplantation
with standard criteria kidney results in significant (p < 0.05) cost
savings compared to either DCD or ECD transplantation.
duced a worse outcome compared to a low DRI organ.
At low MELD scores, there is no survival benefit obtained
from liver transplantation and this is exacerbated when
high DRI livers are used. However, in patients with high
MELD scores, transplantation with livers from any DRI cat-
egory provided significant survival advantage compared to
remaining on the waitlist.
Randall Sung (University of Michigan) reviewed the re-
sults of the recently implemented ECD allocation system
for kidney transplantation. Recovery and transplantation of
ECD kidneys have increased since implementation, while
delayed graft function rates and graft survival have not
changed (7). There is no association between transplant
outcome and either biopsy findings or machine perfusion,
but these two factors continue to be important determi-
nants of ECD kidney discard (8). There is also great variation
in discard rates of ECD kidneys by geographic areas (Fig-
ure 6). This suggests that maximal utilization of ECD kid-
neys requires development of mechanisms to shift these
organs quickly from low to high utilization areas. While
there is a disadvantage for graft survival that applies equally
to all categories of ECD kidney recipients compared to SCD
organs, benefit analyses suggest a survival advantage to
certain subgroups. Specifically, older and/or diabetic recipi-
ents in regions with prolonged waiting times demonstrate
a significant survival increase compared to waiting for a
SCD kidney (9). The proposed kidney allocation scheme
based on the concept of ‘net benefit’ does not include ECD
kidneys. Therefore, ECD kidneys may represent an impor-
tant alternative for those patients less likely to receive a
kidney transplant under a revised SCD algorithm. A need
for the development of a continuous kidney donor risk in-
dex was identified so that more precise risk information
could be presented at the time of organ offer.
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Figure 6: Transplant survival benifit by MELD and donor risk
index. Comparison of the survival benefit of liver transplantation
by MELD and DRI. At the same MELD scores, high DRI organs
produced worse outcomes than low DRI organs. At low MELD
scores, high DRI organs produce no survival benefit. However, at
high MELD scores, transplantation with any DRI offers survival
benefit compared to continued waiting on the list.
Jeevanandam (University of Chicago) discussed the use of
ECD donors in heart transplantation. As was seen in kid-
neys and livers, the use of an ECD heart was associated
with inferior results compared to SCD hearts. However,
survival following ECD heart transplantation is clearly su-
perior to remaining on the waiting list or treatment with a
left ventricular assist device. Spurred on by the significant
short term waiting list mortality, heart transplant centers
at the University of Chicago and UCLA, have begun to use
hearts from donors over 50, those with CAD, poor function
or inotrope use, size mismatches and long preservations
times. This has resulted in a 33% increase in the num-
ber of donors. The creation of alternative lists of patients
willing to take these organs has ensured efficient use of
the available organs. Additional important principles include
avoidance of multiple recipient risk factors, optimization of
cardiac performance prior to recovery and revascularization
of identified coronary lesions prior to transplant (10–12).
The complexity of evaluating potentially infected donors
was discussed by Emily Blumberg (University of Pennsyl-
vania). Bacterial infections are not considered to be a con-
traindication for donation unless the donor organ is affected
and published guidelines for the treatment of potentially
infectious donors are available (13). The proper course is
less clear when the known or suspected infectious agent
is viral. Some, such as hepatitis B or C, are organ spe-
cific and may be suitable for use in some patients. The
impact of less common infections, such as HTLV 1 and 2 is
unknown. The experience with West Nile Virus (WNV) illus-
trates the dilemma of screening for uncommon or emerg-
ing infections in potential organ donors. The virus may
cause meningoencephalitis, but is usually asymptomatic in
normal individuals. However, in recipients of organs from
WNV positive donors, a 40-fold increase in the incidence of
neuroinvasive disease is noted and outcomes are dismal.
While nucleic acid testing for WNV exists, its availability
and reliability are variable, costly and identify few cases. Ex-
clusion of donors from endemic areas would greatly reduce
an already insufficient organ supply and is not advisable
given the very low rate of actual infections. Current rec-
ommendations are to avoid organ donation from patients
with undiagnosed febrile illnesses, encephalitis, meningi-
tis or flaccid paralysis of unknown etiology. Future efforts
should focus on development of rapid and accurate diag-
nostic tests.
The special circumstances encountered when considering
use of a live donor liver graft from an individual infected
with hepatitis B were reviewed by Chung Mao Lo (Queen
Mary Hospital, Hong Kong). In this instance, donor safety
must be considered as well as recipient outcome. In de-
ceased donor liver transplantation, anti-HBc(core) positive,
HBs(surface) antigen negative donor organs are routinely
offered to HbsAg positive recipients. Reactivation of hep-
atitis B virus is expected in immunosuppressed individuals,
and does not appear to differ regardless of donor source.
However, in LDLT, both graft and remnant need to regen-
erate, and the effect of hepatic regeneration on viral re-
activation is not well studied. Their experience suggests
that liver function and hepatic regeneration in both the
donor and recipient is not affected by donor seropositiv-
ity for HBc (14–16). This example also highlights the need
to factor cultural realities into allocation schemes. In Asia,
where deceased donor transplantation is a limited option
and the prevalence of hepatitis B exposure is large, exclu-
sion of anti-HBc positive donors would significantly reduce
the rates of transplantation.
Living donors
The shortage of deceased donor organs has led to the pre-
dictable expansion of live donor transplantation for most
categories of recipients. Kidney transplantation has the
greatest experience in the use of living donors—the num-
ber of live donor kidney transplants frequently exceeds
the number of deceased donor transplants in a report-
ing period (1). Despite this and the increased use of ECD
donors described above, patients continue to be wait-
listed for extended periods. Dorry Segev (Johns Hopkins)
described strategies that help patients with willing, but
incompatible, living donors. Plasmapheresis/intravenous
immunoglobulin/anti-CD20 can be used to eliminate or re-
duce to manageable levels the antibodies preventing trans-
plantation in ABO or HLA crossmatch incompatible pairs
(17–19). Another potential means for increasing transplant
rates is ‘paired donation’ in which two or more donor-
recipient pairs with reciprocal incompatibilities, agree to
exchange donated organs. This results in a net gain of 2
donor organs and removal of 2 recipients from the waiting
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list (20,21). A variety of matching algorithms and consortia
have developed, which increases the likelihood of identi-
fying a match for individual donor-recipient pairs, and also
increases the possibility of having exchanges among mul-
tiple pairs, or ‘domino’ paired donation (22).
The use of living donors in liver transplantation is increas-
ing, especially in areas with long waitlist times (2). The over-
all incidence of live donor liver transplants (LDLT) peaked
at 10% of the total number of liver transplants performed
in 2001 (3). Since then, the percentages have decreased to
5% of the total (∼320 LDLT/year). In regions where the av-
erage MELD score for DDLT is 25 or greater (Regions 1, 5,
7 and 9), the percentage of patients undergoing LDLT con-
tinues to increase and currently represents approximately
10% of all liver transplants. Kim Olthoff (University of Penn-
sylvania) reviewed the results obtained thus far in the Adult
to Adult Living Liver (A2ALL) donor transplantation study
(23–28). Older recipient age and center experience of less
than 20 cases was associated with increased graft failure.
LDLT is associated with reduced waitlist mortality and post-
transplant patient and graft survival is equivalent to de-
ceased donor liver transplantation (DDLT) in experienced
centers. Rejection rates, HCV recurrence and cumulative
risk of fibrosis were also similar. Recurrence free survival
for patients transplanted for hepatocellular carcinoma was
significantly lower for LDLT recipients compared to DDLT.
This may reflect the larger number of patients with T3
pathology on their explants.
Olthoff also reported on donor morbidities experienced af-
ter donor hepatectomy. Overall rehospitalization rate was
12% while the overall complication rate was 38%. Specific
complications included bile leaks (9.2%), hernias (5.6%),
psychological (4%) and pulmonary (6%). The majority of
donor complications was Clavien grade 1 or 2 with only 2%
experiencing grade 3 complications. There were 4 donor
deaths during the study period but only one was donation
related. The others were late occurring (accident, drug over
dose and suicide) (29).
Utilization of living donor intestinal transplantation was re-
viewed by Benedetti (University of Illinois, Chicago). He
cited that mortality on the waitlist was higher than for
any other organ, especially in the pediatric age group. Ad-
vantages of live donation including reduction of ischemic-
reperfusion injury, potential for better HLA matching and
optimal gut/graft decontamination were highlighted. Disad-
vantages included potential harm to the donor, technically
difficult implantation due to a shorter vascular pedicle and
a smaller graft. Combined pediatric liver-intestine grafts,
either simultaneous or sequential, had better outcomes
than recipients of isolated small bowel grafts. Recipients
of combined grafts (n = 5) reported only 1 graft failure, and
no rejection episodes or patient deaths while 2 recipients
of isolated small bowel grafts (n = 5) died from subsequent
liver failure.
Mark Barr (University of Southern California) discussed the
use of living donors in lung transplantation (30,31). This
procedure is unique in that it requires two donors for each
recipient; one donor will give a right lower lobe while the
other donates a left lower lobe. The most common recipi-
ent diagnosis is cystic fibrosis (86%). Comparable survival
rates are observed in adult and pediatric recipients and no
significant difference from recipients of deceased donor
grafts is observed. Recipients of live donor lobar trans-
plants appear to have a decreased incidence of bronchi-
olitis obliterans at all time points compared to published
incidence in deceased donor recipients. Ventilator depen-
dence at time of transplant was associated with poor out-
come. He reports that 80% of donors had no perioperative
complications. Donor complications occurred more often
in right lobe donors, and the most common complication
was need for a thoracostomy tube for greater than 14 days.
Long-term follow-up of donor outcomes and functional ef-
fects is recommended.
Ethical issues arising from the organ shortage crisis
Any allocation strategy for a life-saving scarce resource will
be unavoidably entwined with ethical issues given that
the end result of the strategy is that while some lives
will be saved, others will not. This reality was reflected
in the content of many presentations and the discussions
that followed. James Childress (University of Virginia) pre-
sented the Institute of Medicine (IOM) report on increas-
ing the rates of organ donation (32). They concluded that
presumed consent for organ donation is not currently a
realistic approach in the United States and that empha-
sis should be on including organ donation as part of quality
end-of-life care plans. He reported that the IOM did not rec-
ommend implementation of incentivised donation at this
time, although he did not rule out future implementation.
The report also recommended exploration of ways to uti-
lize people who succumb to out-of-hospital cardiac arrest
as donors.
The need to provide patients informed consent regarding
the quality of the organ being offered for transplant was
discussed in several talks. Drs. Arthur Caplan and James
Allan had a lively debate on this subject with Dr. Caplan
arguing for complete disclosure. He felt that the principles
of patient autonomy and dignity require nothing less, es-
pecially when potentially risky therapies are offered; to do
less undermines the trust that is the cornerstone of the
doctor-patient relationship (33). Dr. Allan acknowledged a
patient’s right to autonomy, but argued that society rou-
tinely limits individual autonomy when it interferes with
the greater good. He cited triage of medical services at
disaster scenes noting that some are forced to wait while
the available medical care is directed toward others in more
urgent need (34). Kinkhabwala (Montefiore) suggested dis-
closing what a reasonable person would need to know to
make an informed decision, including the success rates
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with the type of organ in question. He suggested that the
discussion occur during the evaluation/listing process and
that consenting patients be placed on both standard and
alternative lists (35). John Renz (NY-Presbyterian) pointed
out that transplantation with high-risk organs such as those
infected with HTLV might require formal IRB approval in ad-
dition to patient consent (35).
Finally, the ethics of incentivised donation were debated
by Arthur Matas (University of Minnesota) and Frank Del-
monico (Massachusetts General Hospital). Matas sug-
gested a regulated system of organ ‘sales’ that would in-
sure adequate safeguards to both the donor and the quality
of organ procured. He argued that the result would be an
increase in the overall number of transplants and a corre-
sponding decrease in the number of transplant preventable
deaths (36). Delmonico argued against the practice, citing
the increase in donations in recent years, the potential for
additional increases with increased donor awareness ed-
ucation and the significant decreases in familial donation
documented in systems allowing overt organ sales (37,
38).
Summary
The symposium provided transplant professionals an op-
portunity to explore various options for dealing with the
inadequate supply of organs for transplantation. It is clear
that living donation and non-standard deceased donation
are the solutions in current favor. Once the transplant team
has sufficient experience, the results for recipients of liv-
ing donor organs are equal or superior to those for stan-
dard criteria deceased donors. The short-term results for
recipients of ECD donor organs are inferior to those ob-
tained with SCD donors, but appear acceptable in many
instances considering the high mortality associated with
remaining on the waitlist. However, the true value of this
strategy cannot be assessed until long-term follow-up is
available.
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